ADARx Pharmaceuticals (NASDAQ:ADRX) Stock: Insider Sr One Capital Management, Llc Acquires 1,600,000 Shares

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) major shareholder Sr One Capital Management, Llc acquired 1,600,000 shares of the company’s stock in a transaction that occurred on Monday, September 28th. The stock was acquired at an average price of $17.00 per share, with a total value of $27,200,000.00. Following the acquisition, the insider owned 5,554,094 shares in the company, valued at $94,419,598. The trade was a 40.46% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

ADARx Pharmaceuticals Price Performance

Shares of ADRX stock traded up $0.55 on Tuesday, hitting $20.64. The company had a trading volume of 1,299,367 shares, compared to its average volume of 1,252,283. ADARx Pharmaceuticals, Inc. has a twelve month low of $18.50 and a twelve month high of $23.21.

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based medicines for immune-mediated and other serious diseases. The company is headquartered in San Diego, California, and uses proprietary technologies designed to modulate disease-related proteins at the RNA level.

ADARx’s pipeline includes investigational therapies intended to address conditions involving the complement system, coagulation pathways and other biologic mechanisms. Its programs are designed to provide targeted, durable treatment through approaches such as RNA interference and related forms of RNA-based therapeutic intervention.

Founded in 2018, ADARx has advanced its drug candidates through preclinical and clinical development and has pursued regulatory and clinical activities in the United States and other international markets.